Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure.[1][2][3] In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year.[4] In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade.[5] By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas.